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ABSTRACT
Extracellular vesicles (EVs), including microvesicles and exosomes, mediate intercellular signalling
which has a profound role in cancer progression and in the development of metastasis.
Internalisation of EVs can prompt functional changes in the recipient cells, the nature of which
depends on the molecular composition and the cargo of the EVs. We hypothesised that the meta-
static stage of cancerous parent cells would determine the uptake efficacy and the subsequent
functional effects of the respective cancer cell-derived EVs. To address this question, we compared
the internalisation of EVs derived from twometastatic site-derived prostate cancer cell lines (PC-3 and
LNCaP), human telomerase reverse transcriptase immortalised primary malignant prostate epithelial
cells (RC92a/hTERT), and a benign epithelial prostate cell line (PNT2). EVs isolated from the metastatic
site-derived PC-3 and LNCaP cells were more efficiently internalised by the PC-3 and PNT2 cells
compared to the EVs from the primary malignant RC92a/hTERT cells or the benign PNT2 cells, as
determined by high content microscopy, confocal microscopy, and flow cytometry. EV uptake was
also influenced by the phase of the cell cycle, so that an increased EV-derived fluorescence signal was
observed in the cells at the G2/M phase compared to the G0/G1 or S phases. Finally, differences were
also observed in the functions of the recipient cells based on the EV source. Proliferation of PNT2 cells
and to a lesser extent also PC-3 cells was enhanced particularly by the EVs from the metastatic-site-
derived prostate cancer cells in comparison to the EVs from the benign cells or primary cancer cells,
whereas migration of PC-3 cells was enhanced by all cancerous EVs.
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Introduction
Exchange of molecular information during intercellular
communication is essential for cell survival and func-
tion. In addition to soluble factors, this communication
is mediated by cell-derived extracellular vesicles (EVs),
which are internalised by recipient cells during normal
physiological, but also during pathological processes
[1,2]. EVs, most likely released by all cell types, are a
heterogeneous population of vesicles, comprising e.g.
microvesicles (MVs) (~100–1000 nm diameter) and
exosomes (EXOs) (~50–150 nm diameter) [3]. The
diversity of the vesicles within the EV pool from a
given cell is dependent on the state of the parent cell
and the conditions relating to e.g. cell growth, activa-
tion, and cellular microenvironment [3,4].
EVs are gaining increasing interest due to their ability
to impact cellular reprogramming of the recipient cells by
the delivery of functional molecules, from nucleic acids to
proteins, lipids, and metabolites [5–9]. The delivery of the
EV cargo has been shown to contribute to the transforma-
tion of the recipient cell phenotype during tumour devel-
opment and to the metastatic niche formation [10–13],
and cancer-derived EV adhesion molecules have been
shown to predict the site of metastasis [14]. Also regarding
prostate cancer (PCa), there is increasing evidence sup-
porting an active role of EVs in PCa progression by
stimulating e.g. malignant cellular transformation
[15,16], the exchange of molecular information with
neighbouring cells [9,17,18], fibroblast activation [19],
and osteoblast differentiation during metastasis [20].
Examples of EV-borne PCa molecular secretome include
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the abundance of certain microRNAs [21], proteins
[22,23], and gDNA harbouring tumour-related mutations
[24]. Recently, we showed that metastatic PCa-derived
EVs carried distinctly enriched mRNA signatures differ-
ent from each other and from the benign prostate epithe-
lial EVs, and that these signatures could be associated with
the stage of tumour progression [25]. Specific mRNA
cargo of PCa EVs has been associated with transcriptomic
changes in PCa cells [26] and the predictability of disease
aggressiveness [27]. However, to date, no study has sys-
tematically addressed the uptake and functional properties
of EVs released from prostate cells with varying degrees of
malignancy in the same experimental settings.
For the present study, we isolated and compared EVs
from four prostate cell lines: metastatic site-derived
LNCaP and PC-3 cells, the human immortalised primary
malignant prostate epithelial RC92a/hTERT cells, and the
benign prostate epithelial PNT2 cells. We show that the
efficiency of the EV uptake depended on the metastatic
status of the parent cells as well as on the cell cycle phase
of the recipient cells. Finally, internalisation of the meta-
static cell-derived EVs was shown to efficiently promote
proliferation and migration in recipient cells.
Material and methods
Cell lines and culture conditions
PCa metastatic site-derived LNCaP and PC-3 cells
(ATCC, Manassas, VA, USA), human immortalised
benign prostate epithelial PNT2 cells (ECACC,
Salisbury, UK), and human immortalised primary malig-
nant prostate epithelial RC92a/hTERT cells [28] were
used in the study. PNT2 and RC92a/hTERT cells were
grown in serum-free keratinocyte medium supplemented
with bovine pituitary extract and human recombinant
epidermal growth factor. LNCaP and PC-3 cells were
grown in RPMI 1640 andDMEM/F12media respectively,
supplemented with 10% EV-depleted foetal bovine
serum. All media were supplemented with 100 IU ml–1
of penicillin and 100 μg ml–1 streptomycin and filtered
through 0.22 μm filter (Merck Millipore, Merck KGaA,
Darmstadt, Germany) before addition to cells. The EV-
depleted serum was produced by ultracentrifugation at
110,000 × gavg for 16 h using a 50.2 Ti rotor (Beckman
Coulter, Brea, CA, USA), followed by filtration through a
0.22 μm filter. Cells were grown at 37°C and 5% of CO2
atmosphere and maintained in their own media during
experiments. All reagents were obtained from Thermo
Fisher Scientific (Thermo Fisher, Waltham, MA, USA).
PNT2 and PC-3 cell growth was analysed as index dou-
bling times using RTCA iCELLigence machine (ACEA
Biosciences, San Diego, CA, USA). PC-3 and PNT2 cells
were divided in their respective mediums on E L8 PET-
plates in twofold dilution series (40,000 to 5000 cells/well)
in duplicates and allowed to attach for 30 min at RT
before the plates were transferred to the iCELLigence
machine and the program for proliferation was used.
The optimal growth density was used for doubling time
analysis within 48 h after seeding.
EV isolation and labelling
When cells reached 80% confluence, which was achieved
in three days by PC-3 cells and in four days by LNCaP,
RC92a/hTERT and PNT2 cells, the complete cell-condi-
tioned medium was collected and centrifuged at 1000 × g
for 10 min and 2500 × g for 25 min to remove cell debris
and apoptotic bodies. The supernatant was centrifuged at
20,000 × g for 60 min using a SLA 1500 rotor (Sorvall) to
obtain the 20K MV-enriched fraction. The resulting
supernatant was ultracentrifuged at 110,000 × gavg for
2 h using an Optima-LE 80K ultracentrifuge, 50.2 Ti
rotor, k-factor 143.3 (Beckman Coulter) to obtain the
110K EXO-enriched fractions. The pellets were resus-
pended in DPBS (Thermo Fisher Scientific) and stored
at −80°C. For controls, the completed cell media that has
not been in contact with cells was subjected to EV isola-
tion. Particle counts close to background levels of buffers
were identified, and were at least 100-fold lower com-
pared to the MV and EXO samples.
EVs were labelled with fluorescent lipophilic tracers:
DiIC18(5)-DS (DiIC18) (1–2 μg ml
–1) or SP-DiOC18(3)
(DiOC18) (2 μg ml
–1) (Molecular Probes, Thermo
Fisher Scientific) for 20 min at 37°C, and the unbound
dye was removed by ultracentrifugation at 110,000 ×
gavg for 1 h using Optima MAX-XP ultracentrifuge
with TLA-55 rotor, k-factor 81.3 (Beckman Coulter).
Efficacy of labelling was verified with flow cytometry
using Apogee A50 micro (Apogee, Apogee Flow
Systems, Hertfordshire, UK). The diluted dye alone
subjected to the same ultracentrifugation protocol as
EVs was used as a mock control. The samples were
measured for 120 s with optimal settings. Then SDS
was added to a final concentration of 0.15% to dissolve
EVs and the samples were re-measured. The change in
the fluorescent intensity of DiOC18-EV samples with
and without SDS was analysed to demonstrate the
specificity of the labelling.
Transmission electron microscopy
EV samples were visualised with a transmission electron
microscope (FEI Tecnai Spirit G2, FEI Company,
Eindhoven, The Netherlands) at 80 kV and a digital
camera (Soft Imaging System GmbH, Münster,
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Germany) as previously reported [24]. Briefly, EV sam-
ples were incubated on glow discharged 200 mesh for-
mvar copper grids for 2 min at 4°C. Next, the grids were
washed with distilled water, negatively stained with 2%
aqueous uranyl acetate (Sigma-Aldrich, Merck KGaA),
washed again, and dried in darkness.
Nanoparticle tracking analysis
A nanoparticle tracking analyser (NTA) (Malvern
Instruments Ltd, Malvern, UK) with a LM14 view unit,
blue laser (405 nm, 70mW) and a sCMOS camera
(Hamamatsu Photonics, Hamamatsu, Japan) was used
to measure the size distribution and concentration of
EVs. Triplicate measurements under constant equipment
settings were conducted as follows: camera level 14, auto-
settings off, reproducibility and polydispersity high,
acquisition time 90 s, < 100 particles per image, screen
gain 10, and threshold 10. Data analysis was performed
with the NTA 2.3 software (NanoSight, Amesbury, UK).
Protein quantification and Western blotting
Samples were lysed with RIPA buffer (Pierce, Thermo
Scientific) supplemented with a protease inhibitor mix-
ture (Sigma-Aldrich). Protein concentration was deter-
mined with microBCA protein assay following the
manufacturer’s recommendations (Pierce, Thermo
Scientific). For SDS-PAGE, samples were prepared in
Laemmli buffer (Bio-Rad, Hercules, CA, USA) under
non-reducing conditions, and 25 μg of samples were
loaded in 10–12% Mini-PROTEAN TGX™ gels (Bio-
Rad) and transferred onto Protran nitrocellulose mem-
brane. Membranes were blocked with 5% blotting-
grade non-fat dry milk (Bio-Rad) in Tris-buffered sal-
ine (TBS) for 1 h at room temperature (RT). Primary
antibodies were diluted in 2.5% milk-TBS: mouse
monoclonal anti-CD9 (ALB 6, 1:200) and anti-
GAPDH (7B, 1:500) from Santa Cruz Biotechnology
(Dallas, TX, USA), anti-CD63 (H5C6, 1:200) and anti-
HSP70 (7, 1:2000) from BD Pharmingen (BD
Biosciences, San Jose, CA, USA), were used for
Western blotting. Membranes were washed three
times with TBS-0.1% Tween 20 (TBST), and incubated
for 45 min at RT with the goat anti-mouse IgG-HRP
secondary antibody (Santa Cruz Biotechnology) diluted
in 2.5% milk-TBST. Membranes were washed, incu-
bated with Luminata Crescendo Western HRP
Substrate (Merck Millipore, Merck KGaA, Darmstadt,
Germany), and visualised on Amersham Hyperfilm
ECL (GE Healthcare Ltd, Chicago, IL, USA).
EV uptake analysis by IN Cell Analyser 1000 high
content microscopy
Cells were seeded in black clear bottom 96-well plates at a
density of 4000 cells/well, except PC-3 3000 cells/well, and
labelled with CellBrite Green Cytoplasmic Dye (Biotium,
Freemont, CA, USA), according to the manufacturer’s
instructions. Next day, media supplemented with 109
particles ml–1 of DiIC18-20K MVs or 110K EXOs was
added. Each cell line was incubated with 20K MVs and
110K EXOs from the four cell types. Cells were stained
withHoechst, and analysed using an INCell Analyser 1000
(GE Healthcare, Life Sciences) with a CCD camera and a
20×/0.45 NA objective. The 51,008 polychromic mirror set
was used together with the filter combinations: (405/20 nm
excitation, 535/50 nm emission) for nuclei, (475/20 nm
excitation, 535/50 nm emission) for cytoplasm, and (620/
60 nm excitation, 700/75 nm emission) for DiIC18-EVs.
Analysis was performed using the Developer Toolbox 1.7
software (GE Healthcare) and parameters were kept con-
stant between different samples. The percentage of cells
with DiOC18-EV was quantified using segmentation algo-
rithms selecting EVs as a region of interest (ROI) and
normalised to the total number of cells.
EV uptake and cell cycle analysis by flow cytometry
PC-3 and PNT2 cells were seeded in six-well plates
(Corning Costar, Sigma Aldrich) at 300,000 cells/well and
incubated with different EVs. For cell cycle experiments,
PC-3 cells were incubated with LNCaP or PC-3 EVs. Once
80% confluent, 109 particles ml–1 of DiIC18-EVs (for
uptake) or DiOC18-EVs (for cell cycle) experiments were
added to the cultures. Following incubations at different
time points, cells were washed twice with DPBS, harvested,
fixed overnightwith cold 99% ethanol, and stored at−20°C.
Following ethanol removal and rehydration, cell cycle sam-
ples were stained with 3 μM propidium iodide (Molecular
Probes, Thermo Fisher Scientific) in 4% FBS-DPBS for
15 min at RT. All samples were analysed with a Gallios
flow cytometer (Beckman Coulter) and data were analysed
with FlowJo 10.0 software (FlowJo LLC, Ashland, Oregon,
USA). At least 20,000 events/sample were recorded.
Unstained cellswith andwithout EVswere used as negative
controls to gate the positive populations. Normalised geo-
metric mean fluorescent intensity (gMFI) of cells ± SEM
was presented for each time point.
Immunostaining and confocal microscopy
Cells were plated in chamber slides (Ibidi GmbH,
(Martinsried, Germany) and treated with 109 particles
ml–1 of DiIC18-EVs. After 16 h or 24 h of incubation, the
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cells were fixed with 4% paraformaldehyde, permeabilised
with 0.1% Triton X-100 in 1% BSA-PBS and blocked with
1% BSA-PBS. Samples were stained at 4°C overnight with
anti-CD44 (1:200, gift from Dr Jalkanen, Turku, Finland),
anti-Lamp1 (H4A3, 1:100, IOWA University,
Developmental Studies, USA), polyclonal anti-GM130
(1:100) or anti-EEA1 (1:100) (Cell Signaling, Danvers,
MA, USA). After washing, the cells were incubated for
1 h at RT with Texas red anti-mouse (1:100) or Texas red
anti-rabbit (1:500), (Vector Laboratories, Peterborough,
UK)). The nuclei were stained with DAPI (1 μg ml–1,
Sigma-Aldrich). Confocal images were obtained with
Zeiss Axio Observer with Zeiss LSM 800 confocal module
(Carl Zeiss Microimaging GmbH, Jena, Germany) using
sequential scanning. Co-localisation analyses were con-
ducted using Imaris 7.7.2 software (Bitplane Inc., Belfast,
United Kingdom), selecting DiIC18-EVs channel as ROI.
Thresholds were automatically adjusted by the software
within the ROI. The percentage of ROI material of DiIC18
co-localising with CD44, EEA1, Lamp-1 or GM130 mar-
kers was separately analysed from at least eight images
containing multiple cells.
CFSE proliferation assay
PC-3 and PNT2 cells were seeded in six-well plates and
incubated with 5 µM CellTrace carboxyfluorescein diace-
tate succinimidyl ester (CFSE) (Molecular Probes,
Thermo Fisher Scientific, catalogue number C34554) for
20 min at 37°C. The residual CFSE was removed by three
washes in 2% FBS-PBS and addition of fresh media to the
cells. After 30min, 109 particles ml–1 of EVs were added to
the wells. Cells were harvested in 2%FBS-PBS after 48 h or
72 h, labelled with 7-amino-actinomycin (7-AAD) (BD
Pharmingen) to check cell viability, and immediately sub-
jected to flow cytometry analysis. Fluorescence intensity
was measured from 100,000 events with a FACS Verse
flow cytometer (BD Biosciences, San Jose, CA, USA) and
analysed with FlowJo. Cell proliferation results were
expressed as fold increase compared with controls from
three independent experiments ± SEM.
Migration assay
A radius 24-well assay fibronectin-coated kit (Cell
Biolabs, San Diego, CA, USA) was used to determine
the effect of EVs on cell migration according to manu-
facturer’s instructions. Briefly, PC-3 cells were seeded at
200,000 cells/well. After gel removal, cells were incu-
bated with 1 ml of EV-supplemented or normal media.
Phase-contrast pre-migration images were captured with
an inverted EVOS XL microscope (Thermo Fisher
Scientific) at 10 × magnification. The gap closure was
monitored up to 9 h and data were analysed using
ImageJ 1.49v software (imagej.nih.gov/ij/).
Statistical analysis
Statistics were performed using GraphPad Prism 7.0
(GraphPad Software, San Diego, CA, USA). Unpaired
Student’s t-test, one-way or two-way ANOVA with
Tukey’s multiple comparisons test or Dunnett’s multi-
ple comparisons test were used.
Results
Characterisation of EVs derived from malignant
and benign prostate cells
Cells used in this study were metastatic site-derived
LNCaP and PC-3 PCa cells, RC92a/hTERT telomerase
immortalised malignant primary prostate cells, and
benign immortalised prostate epithelial PNT2 cells.
The 20K MVs and 110K EXOs from these cells were
isolated as enriched subpopulations using differential
centrifugation and used as an entity or as separate
populations. The amount of EVs released was in the
range of 5–50 × 109 particles ml–1 per million cells for
all the cell lines. Similar size distribution and morphol-
ogy were observed for all of these EVs by transmission
electron microscopy (Figure 1(a)). The majority of EVs
in TEM were < 200 nm in diameter. In NTA, the hydro-
dynamic radius of 20KMVs and 110K EXOs overlapped
and was larger for 20K MVs (mean size of
171.5 ± 9.8 nm; n = 12) than for 110K EXOs (mean
size of 135.2 ± 11.5 nm; n = 12) combined for all the four
cell lines. Characteristic EV transmembrane proteins
CD9 and CD63 were detected from the 20K MVs and
110K EXOs with different ratios in comparison to their
parent cells (Figure 1(b)). Similarly, the heat-shock pro-
tein 70 (HSP70) and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) were differentially expressed in the
EV subpopulations and their respective parent cell
lysates. Due to the different cell media, the expression
of these markers in EVs was not, however, directly
comparable between the different cell sources.
The conditions for EV-labelling with fixable lipophi-
lic dyes were optimised for uptake studies generating
DiOC18-labelled EVs that were clearly distinguished
from the unlabelled EVs, as shown by a flow cytometer
especially designed for small particles (Figure 1(c)). To
verify that the fluorescent events were indeed EVs and
not free dye in solution, the DiOC18-EVs were treated
with a mild detergent, which shifted the fluorescent
peak and its intensity by disrupting the EVs and releas-
ing the bound dye (Figure 1(c)). Testing different EV
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concentrations (106–1010 particles ml–1) for the uptake
experiments revealed that 109 particles ml–1 was the
minimal EV concentration required to optimally detect
EV uptake by flow cytometry (Figure 1(d)). This con-
centration was also in range with the EV concentra-
tions secreted by these cells. Exposing cells to even
higher EV concentrations further increased the uptake,
suggesting that the intracellular EV load was not satu-
rated at 109 particles ml–1. To verify that the detected
signal was from internalised EVs and not from EVs
adhered to the cell surface, uptake at 4°C was analysed.
The fluorescent signal in PC-3 cells incubated with
DiIC18-EVs at 4°C was close to the background, as
previously reported [29–31], in contrast to the signal
observed at 37°C (Figure 1(e)).
EVs derived from malignant and benign prostate
cells exhibit different uptake kinetics
To investigate the time-dependent differences in the
EV uptake, we used flow cytometry to quantitate the
average intensity of DiIC18-labelled EVs/cell of the four
different EV sources. Analysis was performed in PC-3
(Figure 2(a)) and PNT2 (Figure 2(b)) cells. A similar
trend of EV uptake kinetics was observed in both cell
types with no significant differences (p > 0.05 two-way
ANOVA) in the total EV uptake with the exception of
more internalisation of PNT2 EVs into PNT2 cells than
PC-3 cells at 12 h (Figure 2(a), 2(b)). Judging by the
intensity/cell, the uptake of the PC-3 and LNCaP EVs
by PC-3 cells was more efficient compared to the
Figure 1. Characterisation and labelling of extracellular vesicles derived from different prostate cell lines. (a) Representative transmission
electron micrographs of more than three independent preparations of EVs isolated from PC-3, LNCaP, PNT2, and RC92a/hTERT cell lines.
Scale bars 200 nm. (b) Qualitative Western blot analysis of CD63, CD9, GAPDH, and HSP70 in the 20K microvesicles (MVs), the 110K
exosomes (EXOs) and cellular lysates. 25 μg of total protein was loaded per lane. Images are representative of three independent
experiments. (c) Representative histograms of the labelling efficacy of EVs using Apogee A50 micro flow cytometer. Unlabelled EVs (Ctrl),
SP-DiOC18(3) labelled EVs (DiO EVs), and SP-DiOC18(3) labelled EVs after 0.15% SDS treatment (DiO EVs + SDS) (n = 2). (d) Histograms of
the uptake of different concentrations of SP-DiOC18(3) labelled EVs (10
6–1010 particles ml–1) by PC-3 cells. Graphs represent the geometric
mean fluorescence intensity (gMFI) of the cells with the different EV concentrations. Bars represent the mean ± SEM of three independent
experiments. (e) Representative histograms of three uptake experiments of DiIC18(5)-DS (DiI) labelled EVs by PC-3 cells after 3 h of
incubation at 37°C and 4°C in comparison to the unstained EVs (Ctrl).
JOURNAL OF EXTRACELLULAR VESICLES 5
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uptake of PNT2 or RC92a/hTERT EVs at 9 and 12 h
(Figure 2(a)). In PNT2 cells, the internalisation of PC-3
and LNCaP EVs was also significantly increased com-
pared to RC92a/hTERT EVs at 9 and 12 h (Figure 2
(b)). The internalisation of PNT2 EVs by PNT2 cells
did not significantly differ from the uptake of PC-3 and
LNCaP EVs at 12 h, when judged by the label intensity/
cell. Confocal microscopy analysis confirmed that the
detected fluorescent signal was indeed from interna-
lised EVs, and not from EVs bound to cell surface
(PNT2 cells, Figure 2(c), 2(d)). Vertical sections gener-
ated by three dimensional analysis of confocal sections
showed that the majority of the fluorescent EV signal
was indeed observed inside the cells (Figure 2(c)).
To analyse the EV uptake by the number of cells
internalising EVs, the percentage of EV-labelled posi-
tive cells was measured using automated high content
microscopy. We also wanted to compare the uptake of
the two EV subpopulations, 20K MVs and 110K EXOs.
For this purpose, metastatic PC-3 (Figure 3(a)) and
benign PNT2 cells (Figure 3(b)) in exponential growth
phase were incubated with PC-3, LNCaP, RC92a/
hTERT, or PNT2-derived DiIC18-labelled 20K MVs
and 110K EXOs. Also in this assay, the uptake of
metastatic site-derived EVs (PC-3, LNCaP) was clearly
more efficient than the uptake of EVs from benign or
primary cancer cells (PNT2, RC92a/hTERT). This phe-
nomenon was detected both in the benign and meta-
static recipient cells (PNT2 and PC-3). Faster and
enhanced uptake of EVs from metastatic origin was
obvious for both the 20K MV and 110K EXO popula-
tions. Thus, for the further analyses, we decided to
investigate the differences between the EVs derived
from metastatic or non-metastatic origin by using a
pooled population of MVs and EXOs.
Cellular localisation of the EV-label after uptake
Next, we analysed the co-localisation of PNT2 and PC-
3 DiIC18-EVs with cellular organelles after 16 h of
Figure 2. Uptake of prostate cell-derived EVs analysed by flow cytometry and confocal microscopy. Fluorescently
labelled EVs (109 particles ml–1) isolated from PC-3, LNCaP, PNT2 and RC92a/hTERT cells were incubated with (a) PC-3 and
(b) PNT2 cells. Cells were analysed by flow cytometry and results were plotted as normalised geometric mean fluorescent
intensity (gMFI) of EV fluorescence in cells. Bars represent mean ± SEM of three independent experiments. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001, two-way ANOVA with Tukey’s multiple comparisons test. (c) Representative confocal
images of two different experiments per group depicting DiIC18(5)-DS labelled EVs (pseudo-coloured green) incubated with
PNT2 cells (plasma membrane marker CD44 pseudo-coloured red and nuclei blue) for 16 h. Middle images (optical sections),
smaller images (vertical sections). (d) Maximum intensity projections created from stack of optical sections. Scale bars, 10 μm.
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continuous uptake in PC-3 cells (Figure 4(a)). Roughly,
30% of the total detected DiIC18 EV-label was localised
in the early endosomes and lysosomes. Only ~5% of
DiIC18-EVs remained at the plasma membrane at 16 h,
indicating efficient internalisation of EVs.
Approximately 10% of DiIC18-label co-localised with
Golgi marker GM130, possibly representing a part of
the EVs that were released from the endosomal com-
partment (Figure 4(b)). The only difference in the
partitioning of the PNT2 and PC-3 EV-label among
the cell organelles was the higher proportion of the
PNT2 EV-label in the early endosomes compared to
the PC-3 EV-label (17% vs. 10%; p < 0.05).
EV uptake by prostate cancer cells is influenced by
the phase of cell cycle
To study whether cell cycle phase [resting phase/Gap1
(G0/G1), DNA synthesis (S), Gap2 (G2) and mitosis
(M)] has an effect on the uptake of EVs, we incubated
PC-3 cells with DiOC18-labelled LNCaP EVs. LNCaP
and PC-3 EVs were selected for this assay, since they
had the highest uptake and the fastest kinetics both in
PC-3 and PNT2 cells (Figure 3). There were no sta-
tistically significant differences in the EV uptake of
cells in the different cell cycle phases during the first
6 h (Supplementary Figure 1A). However, when 20K
MVs were separately analysed, significantly higher EV
signal was observed already at 3 h in the cells at the
G2/M phase (49% increase compared to G0/G1;
p < 0.001) than cells in the S phase (39% increase
compared to G0/G1; p < 0.05) (Supplementary
Figure 1B).
After 24 h and 48 h, the PC-3 cells in the G2/M
phase had acquired a significantly higher EV signal
than the cells in other cell cycle phases, also when the
total population of LNCaP EVs (20K MV and 110K
EXO) was analysed (Figure 5(a), 5(b)). A similar result
was obtained when PC-3 cells were incubated with
labelled PC-3 EVs for 24 h and 48 h (Figure 5(c),
(d)), suggesting that the cellular uptake of EVs is
increased during the G2/M phase. To address the
Figure 3. Uptake of prostate cell-derived 20K microvesicles and 110K exosomes analysed by high content microscopy. Fluorescently
labelled 20K microvesicles (MVs) and 110K exosomes (EXOs) (109 particles ml–1) from PC-3, LNCaP, RC92a/hTERT, and PNT2 cells were
incubated with (a) PC-3 and (b) PNT2 cells for 3, 6, 9, and 12 h. An algorithm that segmented cellular features based on size and
fluorescent intensity was used to analyse all images. Parameters were kept constant between different samples. Results represent
percentage of cells with EVs normalised by the total number of cells. Dots represent the mean ± SEM of two independent experiments.
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possibility that the EV uptake had stimulated the cells
to enter the G2/M phase, we also analysed the distribu-
tion of cells in the different cell cycle phases during
incubation with and without EVs. When cells were
incubated with EVs, the amount of cells in the G2/M
phase of the cell cycle did not increase compared to the
control cells, which were not incubated with EVs
(Figure 5(e), 5(f)).
Figure 4. Localisation of the EV-associated DiIC18(5)-DS label in prostate cells. (a) Cells were incubated for 16 h with PC-3
and PNT2 DiIC18(5)-DS labelled EVs (DiIC18-EVs) (pseudo-coloured green). Cells were immunostained with antibodies against
CD44 for the localisation of plasma membrane (PM), EEA1 for early endosomes (EE), Lamp1 for lysosomes (LYS), and GM130
for Golgi (red), and imaged by confocal microscopy. Scale bars 10 µm. Insets show a zoom into the organelle. (b) The
percentage of the DiIC18 dye co-localisation with each antibody was quantified by Imaris software (n = 42–110 cells). Error
bars represent the mean ± SEM of 8–36 image frames each, *p < 0.05 unpaired t-test.
Figure 5. Uptake of prostate cell-derived EVs in the different stages of the cell cycle. PC-3 cells were incubated with SP-
DiOC18-labelled LNCaP EVs for (a) 24 h or (b) 48 h, and SP-DiOC18-labelled PC-3 EVs for (c) 24 h or (d) 48 h. After fixation,
the cells were stained with propidium iodide, and the SP-DiOC18 fluorescence of cells was analysed by flow cytometry. The
geometric mean fluorescence intensity (gMFI) of cells in each cell cycle phase was normalised by the fluorescence of cells in
the G0/G1 phase. Bars represent mean ± SEM, n = 6 per time point. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001,
one-way ANOVA with Tukey’s multiple comparisons test. Comparison of the percentage of cells incubated with and without
(control) added EVs at the different phases of cell cycle at (e) 3 and 6 h, (f) 24 and 48 h. Error bars represent mean ± SEM
of six independent experiments. *p < 0.05, ***p < 0.001, two-way ANOVA with Tukey’s multiple comparisons test.
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Metastatic PCa EVs enhance proliferation and
migration of prostate cells
The functional effects induced by the uptake of prostate
cell-derived EVs were analysed by measuring prolifera-
tion and migration. Proliferation of PC-3 and PNT2
cells was analysed after 48 h and 72 h incubation with
the EVs from the four different cell lines. At 48 h, no
increase in cell proliferation was observed in the PC-3
cells incubated with any of the EVs (Figure 6(a)), while
at 72 h, PC-3 cell proliferation was significantly
increased in all EV-treated samples compared to the
control without EVs (Figure 6(b)). EVs from the meta-
static PC-3 cells enhanced proliferation more than two-
fold compared with the control, and significantly more
than LNCaP, RC92a/hTERT and PNT2 EVs. In contrast
to PC-3 cells, PNT2 cells showed increased proliferation
already after 48 h incubation with the metastatic site-
derived PC-3 and LNCaP EVs (Figure 6(c)). The biggest
increase in the PNT2 cell proliferation at 48 and 72 h
was observed in the cells incubated with PC-3 EVs,
whose proliferation was twofold to fourfold compared
with the control (Figure 6(c), 6(d)). Also, LNCaP EVs
significantly enhanced PNT2 cell proliferation at 48 h,
whereas no effect was observed with PNT2 and RC92
cell-derived EVs (Figure 6(c)).
Finally, the effect of the different prostate cell-derived
EVs on PC-3 cell migration was investigated. Cell
migration was analysed until the gap closure was
detected (at 6 h). Both metastatic and primary PCa-
derived EVs (PC-3, LNCaP, and RC92a/hTERT) signifi-
cantly stimulated migration of PC-3 cells (Figure 6(e), 6
(f)), whereas the increase in migration by PNT2 EVs was
not statistically significant from the control without EVs.
Discussion
In this study, we compared EVs isolated from prostate
cell lines with different PCa status: metastatic androgen-
unresponsive PC-3, androgen-sensitive LNCaP, primary
cancer cell-derived RC92a/hTERT, and the benign
PNT2 prostate epithelial cells, to ask how the status of
the parental cell line affects the uptake and the cancer-
promoting effects of their EVs. Two different
approaches, flow cytometry and fluorescent microscopy,
were used to study uptake, which allowed less system-
bias for the evaluation of EV uptake in general by
analysing (a) the increase of EV-dependent fluorescence
per cell and (b) the percentage of cells of the whole
population, which were internalising EVs. Despite the
apparent differences in the uptake kinetics at the early
timepoints (Figure 3), the capacity of PC-3 prostate
cancer and the benign PNT2 cells to internalise EVs
was not statistically different between 3 and 9 h. As a
summary, the properties of the PCa EVs rather than the
Figure 6. EVs from the metastatic PCa cells induce proliferation and migration in prostate cells. Cells were incubated with 109 EVs
derived from PC-3, LNCaP, PNT2 and RC92a/hTERT cells or without (wo) EVs for the indicated times. The proliferation of (a,b) PC-3,
and (c,d) the PNT2 cells, was measured using the CFSE-cellular staining by flow cytometry. The results are presented as the
proliferation fold change compared to the control without EVs. Bars represent mean ± SEM from three independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA with Tukey’s multiple comparisons test. (e,f) Migration of PC-3
cells was monitored until gap closure at 6 h in cells incubated with PC-3, LNCaP, RC92a/hTERT, and PNT2-derived EVs or without
EVs. Representative images show gap size at 0 and at 6 h (10× magnification, scale bar 200 μm). The percentage (%) of total
migration of PC-3 cells after addition of EVs or in untreated control without EVs was calculated. Bars are mean ± SEM from six
independent experiments. *p < 0.05, ***p < 0.001, one-way ANOVA with Dunnett’s multiple comparisons test.
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type of the recipient cells determined the efficiency and
the kinetics of the uptake, so that the EVs derived from
the cells of metastatic origin were more effectively inter-
nalised than those from benign or primary PCa cells.
Our results are in line with those of Ronquist et al. [32]
showing both faster kinetics for PC-3 EXOs compared
to non-cancerous prostasomes, and a somewhat
enhanced uptake to the benign CRL2221 prostate cells
at early time points. Confirming our previous results
with PC-3 and LNCaP cells [33], no differences in the
trends of the uptake of the 20K MV and 110K EXO
enriched subpopulations were observed.
More than the cancer vs. non-cancerous status of the
recipient cells, the phase in the cell cycle affected the EV
uptake. EV internalisation during the G2/M phase was
enhanced in comparison to the G0/G1 and S phases.
Although our data cannot fully exclude the possibility
that the higher EV signal in the mitotic cells was due to
the stimulation of mitosis by EVs, we did not observe
any increase in the proportion of cells in the G2/M
phase, when the cells incubated with EVs were com-
pared to the control without EVs. Supporting our find-
ing, the internalisation of artificial nanoparticles was
also reported to be most efficient at the G2/M phase
[34]. This is to our knowledge the first observation of
the effect of the cell cycle on EV uptake. Enhanced EV
uptake by actively dividing cancer cells could be a way to
further stimulate cancer cell growth, as EVs in general
have been shown to promote cell proliferation [35–38].
Several mechanisms for cellular uptake of EVs have
been postulated [39], including energy-dependent
receptor-mediated endocytosis (clathrin-mediated and
caveolin-mediated) [40,41], micropinocytosis [41,42],
phagocytosis [31,43], and plasma membrane or endo-
somal-mediated fusion [44,45]. In our experiments,
roughly 30% of the fluorescent EV label was co-loca-
lised with the endo-lysosomal compartment, which is
in line with the concept that EVs are taken up through
endocytosis [40,41], although the possibility of the EV
fusion at the plasma membrane could not be excluded.
Strikingly, metastatic site-derived EVs were most effi-
ciently internalised by both prostate cancer and benign
cells. We speculate that the faster internalisation and
intracellular trafficking of metastatic cancer cell-derived
EVs could depend on, for example, their surface protein
composition [46]. In line with this hypothesis, trypsinisa-
tion of the outer surface proteins from 20K MVs
decreased their uptake in PC-3 cells, when indirectly
measured as EV-delivered paclitaxel cytotoxicity [33].
Recently, also an ATP-usage dependent differential
uptake of prostasomes and PC-3 cell-derived EXOs by
normal and prostate cancer cells was described, which
may offer a mechanism for the differential uptake [32].
The higher co-localisation of the PNT2 EVswith the early
endosomes compared to the PC-3 EVs could reflect a
slower uptake of the non-cancerous EVs, or for example,
different intracellular trafficking. Since the lipophilic dyes
cannot be used to follow the EV cargo after cell entry,
future studies with a combined labelling of EV lipids and
nucleic acids or proteins are needed for a better insight of
the EV trafficking inside the cell.
Finally, supplementing previous findings [46,47], our
data showing that themetastatic cell-derivedEVs enhanced
proliferation and cell migration of cancer and non-cancer-
ous cells supports the concept that the metastatic EVs
promote tumour-benefiting functions. In this respect, the
finding that the benign cells rapidly and efficiently inter-
nalised the metastatic EVs may be of significance. Our
results also support the earlier findings of an active role of
EVs in PCa progression [48] and warrant further broad
“omics” approaches to reveal the EV-borne molecular
machinery responsible for these effects. We and others
have previously shown that the genomic [24], transcrip-
tomic [25], proteomic [49,50], metabolomics [51] and lipi-
domic [52] profiles of PCa EVs are variable and dependent
on the cancerous status of the parent cell. Suggested by our
study, broader cell-line based comparisons may help to
dissect the molecular differences modifying the behaviour
of prostate cells in the tumour and/or metastatic environ-
ment. Considering the already known importance of the
EV-mediated communication in the PCa tumour progres-
sion [53,54]. it will be relevant to systematically compare
EVs of different origins and to analyse their cargo to
unravel the EV-based communication mechanisms
between cancerous and non-cancerous cells.
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